Previous 10 | Next 10 |
Leverkusen, Germany, March 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the Cologne Local District Court ( Amtsgericht ) dismissed Mr. Hansjörg Plaggem...
Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a conference call to be held tomorrow to provide a detailed corporate update on its acqui...
Biofrontera ( BFRA +2.4% ) enters into an agreement with Maruho, to acquire Cutanea Life Sciences for an initial purchase price of $1; Maruho holds ~20% of Biofrontera. More news on: Biofrontera AG, Biofrontera AG, Merger & acquisition news, Healthcare stocks news, Re...
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today entered into an agreement to acquire all...
Ultra-thinly traded Biofrontera ( BFRA +4.1% ) is up an 8x surge in volume, albeit on turnover of only 12,700 shares, on the heels of preliminary data from a Phase 3 clinical trial evaluating conventional photodynamic therapy (PDT) with topical gel Ameluz (aminolevulinic acid hydrochlo...
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today received positive preliminary results for the primary endpoint of its Phase III cl...
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today signed an agreement to continue the expired research cooperation with Maruho Co., Ltd., Osaka, Japan (“Maruho”...
Biofrontera ( BFRA ; BFFTF ) has been gradually shifting from a biotech company into a focused pharmaceutical company with specialization in dermatology. The central turning point was the European approval of the self-developed medication Ameluz for the photodynamic therapy of actinic keratos...
Leverkusen, Germany, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that its wholly owned US-subsidiary Biofrontera Inc. earned a Silver Stevie Award for outstanding ...
Leverkusen, Germany, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has implemented all necessary safety measures defined in the new Commission Delegated Regulation (EU...
News, Short Squeeze, Breakout and More Instantly...
Biofrontera AG Company Name:
BFRA Stock Symbol:
NASDAQ Market:
Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the N...
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal ...
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. K ...